</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>In this population-based retrospective cohort analysis of adult HIV-infected patients managed under normal programmatic conditions in public HIV treatment facilities in Brazil, we observed a statistically significantly lower (80%, p&lt;0.01) incidence of TB in patients prescribed HAART compared to patients who remained ART-naïve. This effect of HAART remained statistically significant even when controlling for the patients' baseline immunological status, and other important characteristics and interventions (<a href="#pone-0000826-t004">Tables 4</a> and <a href="#pone-0000826-t005">5</a>). Though treatment with ART non-HAART also resulted in a lower TB incidence rate, the reduction did not reach statistical significance (p = 0.08). The findings in this study serve to validate similar findings in previous, more controlled studies, and demonstrate that it is possible for national programs to provide access to HAART under “real world” conditions, and in doing so, reduce the risk of the most common OI of adults living with HIV—TB <a href="#pone.0000826-Dheda1">[19]</a>–<a href="#pone.0000826-Jones1">[22]</a>.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>In Brazil, it is customary for HIV treatment facilities to take over the care of newly diagnosed HIV-infected patients in the public sector, and thereafter, provide longitudinal comprehensive clinical management and ART, as indicated <a href="#pone.0000826-Levi1">[25]</a>. According to the WHO, 86% of diagnosed and eligible HIV-infected patients in Brazil were receiving ART in 2004, a proportion superior to that of low and middle income countries (e.g., Peru, 18%); and similar to that of developed countries in South America such as Argentina and Chile (both 100%) <a href="#pone.0000826-World3">[26]</a>. However, while access to ART remains very important, a significant impact in the reduction TB incidence for people living with HIV is unlikely unless a large proportion of the subset who are unaware of their HIV serostatus are tested, and national programs are able to deliver high quality comprehensive clinical care, including effective provision of ART to this population.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>The patients who developed TB disease in our study had similar risk factors for TB as HIV-infected patients in other settings, and 66% eventually received HAART <a href="#pone.0000826-Hopewell1">[1]</a>, <a href="#pone.0000826-Raviglione1">[8]</a>, <a href="#pone.0000826-Bleed1">[11]</a>, <a href="#pone.0000826-Jones1">[22]</a>, <a href="#pone.0000826-Selwyn1">[34]</a>, <a href="#pone.0000826-Badri2">[35]</a>. Nevertheless, 11 (4%) patients developed TB disease despite receiving HAART. A higher proportion of patients with TB had median baseline CD4+ T-lymphocyte counts &lt;200 cells/mm<sup>3</sup> compared to patients without TB (57% vs. 37%, respectively. <em>Χ</em><sup>2</sup>, p = 0.01). This suggests that those who developed TB may have been more immunocompromised at baseline than patients remaining TB free; however, the median baseline absolute CD4+ T-lymphocyte count and baseline WHO clinical staging characteristics were not significantly different between the two groups. We cannot exclude the possibility, however, that the study lacked the power to detect subtle but clinically important immunological differences among groups. In areas of high TB prevalence, TB can occur at all levels of CD4+ T-lymphocyte count, though ART-naïve patients who develop TB frequently present with low CD4+ T-lymphocyte counts prior to TB diagnosis <a href="#pone.0000826-Mukadi1">[36]</a>, <a href="#pone.0000826-Wolday1">[37]</a>. Both HAART and non-HAART regimens have been shown to raise CD4+ T-lymphocyte counts and improve the clinical status of HIV-infected patients with and without concomitant OI <a href="#pone.0000826-Badri1">[20]</a>, <a href="#pone.0000826-Eron1">[38]</a>, <a href="#pone.0000826-Lawn1">[39]</a>. This suggests that other factors may be affecting TB disease risk after initiating ART. Indeed, evidence exists to suggest that HAART is unable to fully restore the immune response to <em>Mycobacterium tuberculosis</em> in HIV-infected patients, leading to a chronically heightened TB risk over an increased lifespan <a href="#pone.0000826-Lawn1">[39]</a>–<a href="#pone.0000826-Jorda1">[41]</a>. Addressing this heightened risk poses a challenge for the future control of TB; however, growing evidence also suggests that this risk may be mitigated by early initiation of HAART with corresponding high levels of treatment adherence <a href="#pone.0000826-Williams1">[24]</a>, <a href="#pone.0000826-Jorda1">[41]</a>, <a href="#pone.0000826-Maher1">[42]</a>. Fortunately, currently and widely recommended clinical guidelines for the treatment of HIV infection and TB disease are helping to eliminate an important negative factor from the TB/HIV equation—suboptimal ART. Because of the timeframe selected for this study, 1995–2001, it was not uncommon, early within this time interval, to document ART regimens consisting of single and dual ARV agents. Nevertheless, we saw a corresponding shift toward HAART (data not shown) in this study as scientific thought about ART gradually evolved after 1995 <a href="#pone.0000826-Jorda1">[41]</a>. Attention to other factors such as facility infection-control, active case finding, and wider use of appropriately administered IPT could be instrumental in further reducing TB disease risk in HIV-infected individuals (Golub JE, et al. Tuberculosis incidence by HAART and isoniazid prophylactic therapy in HIV-infected patients in Rio de Janeiro, Brazil. XVI International AIDS Conference, 2006 Abstract no. MoPE0395) <a href="#pone.0000826-Bucher1">[5]</a>, <a href="#pone.0000826-Fitzgerald1">[9]</a>, <a href="#pone.0000826-SantoroLopes1">[23]</a>, <a href="#pone.0000826-Maher1">[42]</a>–<a href="#pone.0000826-World8">[45]</a>. On-going studies with regard to the use of IPT in HIV infection should elucidate the optimal use of this intervention (Samandari T, et al. Characteristics of people living with HIV-1 screened for isoniazid preventive therapy-Botswana, 2004–2005. AIDS 2006-XVI International AIDS Conference, 2006 Abstract no. MoAB010).</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4"></a><p>Finally, there is now reliable information showing that HIV-related morbidity and mortality in adults and children, including that due to TB disease co-morbidity, can be significantly reduced with the adjunctive use of CTM prophylaxis <a href="#pone.0000826-Wiktor1">[46]</a>–<a href="#pone.0000826-Chintu1">[48]</a>. We found that the mortality rate and overall mortality of the cohort and of severely immunocompromised TB patients was comparable, if not lower, than that observed for HIV infected patients managed and reported in high income countries after 1995 <a href="#pone.0000826-Palella1">[16]</a>, <a href="#pone.0000826-Hung1">[17]</a>, <a href="#pone.0000826-Mocroft1">[49]</a>. And, while many factors clearly confound any mortality considerations in this study, the fact that 46% and 33% of the cohort and of TB patients, respectively, in the study received at least one dose of CTM probably contributed to favorable outcomes in these patients. As is probably the case in many other clinical settings globally, the use of CTM prophylaxis among HIV-infected populations with TB can clearly be improved and, in doing so, independently reduce patient morbidity and mortality.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5"></a><p>Our study population specifically excludes children (age&lt;18 years) and pregnant women. Due to the retrospective and observational design of this study, we were also unable to control for factors specific to (a) patients (e.g., adverse nutritional and psycho-social issues); (b) facilities (e.g., infection control measures); and, (c) programs [e.g., erratic pharmacy drug stocks and diagnostic rigor (e.g., low sensitivity and specificity of X-ray imaging)]. In addition, patients with only one clinic visit were explicitly excluded from the study, and we were unable to consistently determine the degree of patient adherence to therapeutic regimens from patient records. With regards to treatment adherence, however, WHO and others estimate adherence to be approximately 75% among patients on ART in Brazil <a href="#pone.0000826-World4">[27]</a>, <a href="#pone.0000826-Carmody1">[50]</a>.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6"></a><p>An additional limitation of our study was that the majority of the TB diagnoses recorded were made, primarily, on clinical grounds (i.e., presumed); and therefore, an alternative diagnosis to TB cannot be excluded. As the most common opportunistic disease of HIV-infected patients, however, the clinical experience of health care staff in facilities with large HIV patient populations probably lessens this possibility. In addition, TB misdiagnosis would only tend to underestimate the degree of TB incidence reduction by HAART.</p>
<a id="article1.body1.sec4.p7" name="article1.body1.sec4.p7"></a><p>Despite the limitations of the study and the fact that a proportion of study patients received sub-optimal ART before being switched to HAART, the significant reduction in TB disease observed is all the more remarkable. Our findings, however, are not applicable to pediatric patients, and should be interpreted in light of the study limitations.</p>
<a id="article1.body1.sec4.p8" name="article1.body1.sec4.p8"></a><p>We conclude that, in settings of unrestricted access to ART, HAART can have a significant impact on the TB incidence of HIV-infected patients developing. We found that, even under programmatic conditions, a statistically significant reduction in TB incidence of 80% was observed among HIV-infected patients receiving HAART in the public sector in Brazil compared to patients who remained ART-naïve. We demonstrate that, although broad access to ART remains an elusive goal of low and middle income countries, a national policy that drives the effective implementation of a program that manages HIV-infected patients using HAART is an initiative that is not only beneficial in reducing TB disease in HIV-infected patients, but also a feasible one.</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>The authors wish to acknowledge the incalculable contribution of the members of (a) the data abstraction teams; (b) the participating state and municipal departments of health, in particular: Dr. Lia Selig (Rio de Janeiro), Dr. Katia Bassichetto (Sao Paulo), and Dr. Artur Kalichman (Sao Paulo); (c) the PNDA and PNCT of the Brazil MoH; and of Dr. Luis Alberto, Dr. Edgardo Cid, Dr. Eduardo Netto, and Ms. Linda Carr, without whose assistance this study would not have been possible.</p>
<a id="article1.back1.ack1.p2" name="article1.back1.ack1.p2"></a><p>The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: AM KL CW DG. Performed the experiments: AM DG. Analyzed the data: AM MM. Contributed reagents/materials/analysis tools: GS JS CW PP DG. Wrote the paper: AM. Other: Helped conceive and design the experiments, specifically the study protocol: DB. Helped perform the experiments specifically with the patient record abstraction: LJ. Provided logistical support: PP JS GS. Provided administrative support: PP. Helped train the remaining data abstractors in the team: LJ.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0000826-Hopewell1" id="pone.0000826-Hopewell1"></a>Hopewell PC, Chaisson RE (2000)  Tuberculosis and human immunodeficiency virus Infection. In: Reichman LB, Hershfield ES, editors. Tuberculosis, a comprehensive approach, 6<sup>th</sup> ed. New York: Marcel Dekker, Inc. pp. 525–552.  <ul class="find-nolinks"></ul></li><li><span class="label">2.
              </span><a name="pone.0000826-Grant1" id="pone.0000826-Grant1"></a>Grant AD, Djomand G, De Cock KM (1997) Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS  11: suppl. BS43–S54.  <ul class="find" data-citedArticleID="986040" data-doi="10.1097/00002030-199711000-00010"><li><a href="http://dx.doi.org/10.1097/00002030-199711000-00010" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Natural+history+and+spectrum+of+disease+in+adults+with+HIV%2FAIDS+in+Africa." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Natural+history+and+spectrum+of+disease+in+adults+with+HIV%2FAIDS+in+Africa.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0000826-Corbett1" id="pone.0000826-Corbett1"></a>Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, et al.  (2002) Morbidity and mortality in South Africa gold miners: impact of untreated HIV infection. Clin Infect Dis  34: 1251–1258.  <ul class="find" data-citedArticleID="986018" data-doi="10.1086/339540"><li><a href="http://dx.doi.org/10.1086/339540" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Morbidity+and+mortality+in+South+Africa+gold+miners%3A+impact+of+untreated+HIV+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Morbidity+and+mortality+in+South+Africa+gold+miners%3A+impact+of+untreated+HIV+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0000826-Nunn1" id="pone.0000826-Nunn1"></a>Nunn P, Brindle R, Carpenter L (1992) Cohort study on human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Am J Resp Crit Care Med  146: 849–854.  <ul class="find" data-citedArticleID="986068" data-doi="10.1164/ajrccm/146.4.849"><li><a href="http://dx.doi.org/10.1164/ajrccm/146.4.849" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cohort+study+on+human+immunodeficiency+virus+infection+in+patients+with+tuberculosis+in+Nairobi%2C+Kenya." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cohort+study+on+human+immunodeficiency+virus+infection+in+patients+with+tuberculosis+in+Nairobi%2C+Kenya.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0000826-Bucher1" id="pone.0000826-Bucher1"></a>Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, et al.  (1999) Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS  13: 501–507.  <ul class="find" data-citedArticleID="986012" data-doi="10.1097/00002030-199903110-00009"><li><a href="http://dx.doi.org/10.1097/00002030-199903110-00009" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Isoniazid+prophylaxis+for+tuberculosis+in+HIV+infection%3A+a+meta-analysis+of+randomized+controlled+trials." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Isoniazid+prophylaxis+for+tuberculosis+in+HIV+infection%3A+a+meta-analysis+of+randomized+controlled+trials.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0000826-Daley1" id="pone.0000826-Daley1"></a>Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, et al.  (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med  326: 231–235.  <ul class="find" data-citedArticleID="986022" data-doi="10.1056/nejm199201233260404"><li><a href="http://dx.doi.org/10.1056/nejm199201233260404" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=An+outbreak+of+tuberculosis+with+accelerated+progression+among+persons+infected+with+the+human+immunodeficiency+virus." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22An+outbreak+of+tuberculosis+with+accelerated+progression+among+persons+infected+with+the+human+immunodeficiency+virus.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0000826-DiPerri1" id="pone.0000826-DiPerri1"></a>Di Perri , Cruziani M, Danzi MC, Luzzati R, De Checchi , et al.  (1989) Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet  2: 1502–4.  <ul class="find" data-citedArticleID="986026"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Nosocomial+epidemic+of+active+tuberculosis+among+HIV-infected+patients.&amp;auth=&amp;atitle=Nosocomial+epidemic+of+active+tuberculosis+among+HIV-infected+patients." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Nosocomial+epidemic+of+active+tuberculosis+among+HIV-infected+patients." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Nosocomial+epidemic+of+active+tuberculosis+among+HIV-infected+patients.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0000826-Raviglione1" id="pone.0000826-Raviglione1"></a>Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P (1997) Tuberculosis and HIV: current status in Africa. AIDS  11: suppl. BS115–S123.  <ul class="find" data-citedArticleID="986072"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Tuberculosis+and+HIV%3A+current+status+in+Africa.&amp;auth=&amp;atitle=Tuberculosis+and+HIV%3A+current+status+in+Africa." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis+and+HIV%3A+current+status+in+Africa." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis+and+HIV%3A+current+status+in+Africa.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0000826-Fitzgerald1" id="pone.0000826-Fitzgerald1"></a>Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, et al.  (2000) Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet  356: 1470–1474.  <ul class="find" data-citedArticleID="986030" data-doi="10.1016/s0140-6736(00)02870-1"><li><a href="http://dx.doi.org/10.1016/s0140-6736(00)02870-1" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Effect+of+post-treatment+isoniazid+on+prevention+of+recurrent+tuberculosis+in+HIV-1-infected+individuals%3A+a+randomised+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Effect+of+post-treatment+isoniazid+on+prevention+of+recurrent+tuberculosis+in+HIV-1-infected+individuals%3A+a+randomised+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0000826-Sonnenberg1" id="pone.0000826-Sonnenberg1"></a>Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, et al.  (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet  358: 1687–1693.  <ul class="find" data-citedArticleID="986080" data-doi="10.1016/s0140-6736(01)06712-5"><li><a href="http://dx.doi.org/10.1016/s0140-6736(01)06712-5" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HIV-1+and+recurrence%2C+relapse%2C+and+reinfection+of+tuberculosis+after+cure%3A+a+cohort+study+in+South+African+mineworkers." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HIV-1+and+recurrence%2C+relapse%2C+and+reinfection+of+tuberculosis+after+cure%3A+a+cohort+study+in+South+African+mineworkers.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0000826-Bleed1" id="pone.0000826-Bleed1"></a>Bleed D, Dye C, Raviglione M (2000) Dynamics and control of the global tuberculosis epidemic. Curr Opin Pulm Med  6: 174–179.  <ul class="find" data-citedArticleID="986010" data-doi="10.1097/00063198-200005000-00002"><li><a href="http://dx.doi.org/10.1097/00063198-200005000-00002" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Dynamics+and+control+of+the+global+tuberculosis+epidemic." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Dynamics+and+control+of+the+global+tuberculosis+epidemic.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0000826-GodreyFaussett1" id="pone.0000826-GodreyFaussett1"></a>Godrey-Faussett P, Ayles H (2003) Can we control tuberculosis in high HIV prevalence settings? Tuberculosis  83: 68–76.  <ul class="find" data-citedArticleID="986038" data-doi="10.1016/s1472-9792(02)00083-5"><li><a href="http://dx.doi.org/10.1016/s1472-9792(02)00083-5" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Can+we+control+tuberculosis+in+high+HIV+prevalence+settings%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Can+we+control+tuberculosis+in+high+HIV+prevalence+settings%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0000826-Corbett2" id="pone.0000826-Corbett2"></a>Corbett EL, Watt C, Walker N, Maher D, Williams B, et al.  (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med  163: 1009–1021.  <ul class="find" data-citedArticleID="986020" data-doi="10.1001/archinte.163.9.1009"><li><a href="http://dx.doi.org/10.1001/archinte.163.9.1009" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+growing+burden+of+tuberculosis%3A+global+trends+and+interactions+with+the+HIV+epidemic." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+growing+burden+of+tuberculosis%3A+global+trends+and+interactions+with+the+HIV+epidemic.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0000826-World1" id="pone.0000826-World1"></a>World Health Organization (2002) Strategic framework to decrease the burden of TB/HIV. Geneva: World Health Organization (WHO/CDS/TB/2002.296).   <ul class="find-nolinks"></ul></li><li><span class="label">15.
              </span><a name="pone.0000826-World2" id="pone.0000826-World2"></a>World Health Organization (2002) Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization (WHO/HTM/TB/2004.330).   <ul class="find-nolinks"></ul></li><li><span class="label">16.
              </span><a name="pone.0000826-Palella1" id="pone.0000826-Palella1"></a>Palella FJ Jr, Delaney KM, Moorman AC (1998) Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med  338: 853–860.  <ul class="find" data-citedArticleID="986070" data-doi="10.1056/nejm199803263381301"><li><a href="http://dx.doi.org/10.1056/nejm199803263381301" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Declining+morbidity+and+mortality+among+patients+with+advanced+HIV+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Declining+morbidity+and+mortality+among+patients+with+advanced+HIV+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0000826-Hung1" id="pone.0000826-Hung1"></a>Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, et al.  (2003) Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS  17: 2615–2622.  <ul class="find" data-citedArticleID="986044" data-doi="10.1097/00002030-200312050-00008"><li><a href="http://dx.doi.org/10.1097/00002030-200312050-00008" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Improved+outcomes+of+HIV-1-infected+adults+with+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Improved+outcomes+of+HIV-1-infected+adults+with+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0000826-Girardi1" id="pone.0000826-Girardi1"></a>Girardi E, Palmieri F, Cingolani A, Ammassari a, Petrosillo N, et al.  (2001) Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Sydr  26: 326–331.  <ul class="find" data-citedArticleID="986034" data-doi="10.1097/00126334-200104010-00006"><li><a href="http://dx.doi.org/10.1097/00126334-200104010-00006" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Changing+clinical+presentation+and+survival+in+HIV-associated+tuberculosis+after+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Changing+clinical+presentation+and+survival+in+HIV-associated+tuberculosis+after+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0000826-Dheda1" id="pone.0000826-Dheda1"></a>Dheda K, Lampe FC, Johnson MA, Lipman MC (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis  190: 1670–1676.  <ul class="find" data-citedArticleID="986024" data-doi="10.1086/424676"><li><a href="http://dx.doi.org/10.1086/424676" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Outcome+of+HIV-associated+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Outcome+of+HIV-associated+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0000826-Badri1" id="pone.0000826-Badri1"></a>Badri M, Wilson D, Wood R (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet  359: 2059–2064.  <ul class="find" data-citedArticleID="986006" data-doi="10.1016/s0140-6736(02)08904-3"><li><a href="http://dx.doi.org/10.1016/s0140-6736(02)08904-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Effect+of+highly+active+antiretroviral+therapy+on+incidence+of+tuberculosis+in+South+Africa%3A+a+cohort+study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Effect+of+highly+active+antiretroviral+therapy+on+incidence+of+tuberculosis+in+South+Africa%3A+a+cohort+study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0000826-Girardi2" id="pone.0000826-Girardi2"></a>Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, et al.  (2000) Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS  14: 1985–1991.  <ul class="find" data-citedArticleID="986036" data-doi="10.1097/00002030-200009080-00015"><li><a href="http://dx.doi.org/10.1097/00002030-200009080-00015" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Impact+of+combination+antiretroviral+therapy+on+the+risk+of+tuberculosis+among+persons+with+HIV+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Impact+of+combination+antiretroviral+therapy+on+the+risk+of+tuberculosis+among+persons+with+HIV+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0000826-Jones1" id="pone.0000826-Jones1"></a>Jones JL, Hanson MS, De Cock KM (2000) HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Dis  4: 1026–1031.  <ul class="find" data-citedArticleID="986046"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=HIV-associated+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy.&amp;auth=&amp;atitle=HIV-associated+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HIV-associated+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HIV-associated+tuberculosis+in+the+era+of+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0000826-SantoroLopes1" id="pone.0000826-SantoroLopes1"></a>Santoro-Lopes G, Felix de Pinho AM, Harrison LH, Schecter M (2002) Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis  34: 543–546.  <ul class="find" data-citedArticleID="986074" data-doi="10.1086/338641"><li><a href="http://dx.doi.org/10.1086/338641" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Reduced+risk+of+tuberculosis+among+Brazilian+patients+with+advanced+human+immunodeficiency+virus+infection+treated+with+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Reduced+risk+of+tuberculosis+among+Brazilian+patients+with+advanced+human+immunodeficiency+virus+infection+treated+with+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0000826-Williams1" id="pone.0000826-Williams1"></a>Williams BG, Dye C (2003) Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science  301: 1535–1537.  <ul class="find" data-citedArticleID="986084" data-doi="10.1126/science.1086845"><li><a href="http://dx.doi.org/10.1126/science.1086845" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antiretroviral+drugs+for+tuberculosis+control+in+the+era+of+HIV%2FAIDS." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antiretroviral+drugs+for+tuberculosis+control+in+the+era+of+HIV%2FAIDS.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">25.
              </span><a name="pone.0000826-Levi1" id="pone.0000826-Levi1"></a>Levi GC, Vitoria MA (2002) Fighting against AIDS: the Brazilian experience. AIDS  16: 2373–2383.  <ul class="find" data-citedArticleID="986052" data-doi="10.1097/00002030-200212060-00001"><li><a href="http://dx.doi.org/10.1097/00002030-200212060-00001" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Fighting+against+AIDS%3A+the+Brazilian+experience." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Fighting+against+AIDS%3A+the+Brazilian+experience.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">26.
              </span><a name="pone.0000826-World3" id="pone.0000826-World3"></a>World Health Organization (2007) Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva: World Health Organization (WHO/HTM/TB/2007.376).   <ul class="find-nolinks"></ul></li><li><span class="label">27.
              </span><a name="pone.0000826-World4" id="pone.0000826-World4"></a>World Health Organization (2004) “3 by 5” progress report. Geneva: World Health Organization.   <ul class="find-nolinks"></ul></li><li><span class="label">28.
              </span><a name="pone.0000826-Fleiss1" id="pone.0000826-Fleiss1"></a>Fleiss JL, Levin B, Myunghee CP (2004)  Determining sample sizes needed to detect a difference between two proportions. In: Shewart WA, Samuel SW, editors. 2<sup>nd</sup> ed. Hoboken: John Wiley &amp; Sons. pp. 64–85.  <ul class="find-nolinks"></ul></li><li><span class="label">29.
              </span><a name="pone.0000826-World5" id="pone.0000826-World5"></a>World Health Organization (1990) Acquired immunodeficiency syndrome: interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec  65: 221–224.  <ul class="find" data-citedArticleID="986096"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Acquired+immunodeficiency+syndrome%3A+interim+proposal+for+a+WHO+staging+system+for+HIV+infection+and+disease.&amp;auth=&amp;atitle=Acquired+immunodeficiency+syndrome%3A+interim+proposal+for+a+WHO+staging+system+for+HIV+infection+and+disease." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Acquired+immunodeficiency+syndrome%3A+interim+proposal+for+a+WHO+staging+system+for+HIV+infection+and+disease." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Acquired+immunodeficiency+syndrome%3A+interim+proposal+for+a+WHO+staging+system+for+HIV+infection+and+disease.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0000826-Ministrio1" id="pone.0000826-Ministrio1"></a>Ministério da Saúde do Brasil, Programa Nacional de DST e Aids, Secretaria de Vigilância em Saúde (2006) Recomendacões para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV (versão preliminar). Brasília: Ministério da Saúde do Brasil.   <ul class="find-nolinks"></ul></li><li><span class="label">31.
              </span><a name="pone.0000826-Ministrio2" id="pone.0000826-Ministrio2"></a>Ministério da Saúde do Brasil, Secretaria de Políiticas de Saúde, Departamento de Atencion Básica (2002) Manual técnico para o controle da tuberculose: cadernos de atenção básica, 6<sup>th</sup> ed. Brasília: Ministério da Saúde do Brasil.   <ul class="find-nolinks"></ul></li><li><span class="label">32.
              </span><a name="pone.0000826-Lipman1" id="pone.0000826-Lipman1"></a>Lipman M, Breen R (2006) Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis  19: 20–25.  <ul class="find" data-citedArticleID="986056" data-doi="10.1097/01.qco.0000200543.80712.01"><li><a href="http://dx.doi.org/10.1097/01.qco.0000200543.80712.01" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Immune+reconstitution+inflammatory+syndrome+in+HIV." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Immune+reconstitution+inflammatory+syndrome+in+HIV.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">33.
              </span><a name="pone.0000826-Shelburne1" id="pone.0000826-Shelburne1"></a>Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, et al.  (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS  19: 399–406.  <ul class="find" data-citedArticleID="986078" data-doi="10.1097/01.aids.0000161769.06158.8a"><li><a href="http://dx.doi.org/10.1097/01.aids.0000161769.06158.8a" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Incidence+and+risk+factors+for+immune+reconstitution+inflammatory+syndrome+during+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Incidence+and+risk+factors+for+immune+reconstitution+inflammatory+syndrome+during+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">34.
              </span><a name="pone.0000826-Selwyn1" id="pone.0000826-Selwyn1"></a>Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al.  (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med  320: 545–550.  <ul class="find" data-citedArticleID="986076" data-doi="10.1056/nejm198903023200901"><li><a href="http://dx.doi.org/10.1056/nejm198903023200901" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+prospective+study+of+the+risk+of+tuberculosis+among+intravenous+drug+users+with+human+immunodeficiency+virus+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+prospective+study+of+the+risk+of+tuberculosis+among+intravenous+drug+users+with+human+immunodeficiency+virus+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">35.
              </span><a name="pone.0000826-Badri2" id="pone.0000826-Badri2"></a>Badri M, Pulerwitz T, Wood R, Maarten G (2002) Tuberculosis should not be considered an AIDS-defining illness in areas with high tuberculosis prevalence. Int J Tuberc Lung Dis  6: 231–237.  <ul class="find" data-citedArticleID="986008"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Tuberculosis+should+not+be+considered+an+AIDS-defining+illness+in+areas+with+high+tuberculosis+prevalence.&amp;auth=&amp;atitle=Tuberculosis+should+not+be+considered+an+AIDS-defining+illness+in+areas+with+high+tuberculosis+prevalence." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis+should+not+be+considered+an+AIDS-defining+illness+in+areas+with+high+tuberculosis+prevalence." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis+should+not+be+considered+an+AIDS-defining+illness+in+areas+with+high+tuberculosis+prevalence.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">36.
              </span><a name="pone.0000826-Mukadi1" id="pone.0000826-Mukadi1"></a>Mukadi Y, Perriëns JH, St. Louis ME, Brown C, Prignot J, et al.  (1993) Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet  342: 143–146.  <ul class="find" data-citedArticleID="986066" data-doi="10.1016/0140-6736(93)91346-n"><li><a href="http://dx.doi.org/10.1016/0140-6736(93)91346-n" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Spectrum+of+immunodeficiency+in+HIV-1-infected+patients+with+pulmonary+tuberculosis+in+Zaire." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Spectrum+of+immunodeficiency+in+HIV-1-infected+patients+with+pulmonary+tuberculosis+in+Zaire.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">37.
              </span><a name="pone.0000826-Wolday1" id="pone.0000826-Wolday1"></a>Wolday D, Hailu B, Girma M, Hailu E, Sanders E, et al.  (2003) Low CD4+ T-lymphocyte T-cell and high viral load precede the development of tuberculosis disease in a cohort of HIV-positive Ethiopians. Int J Tuberc Lung Dis  7: 110–116.  <ul class="find" data-citedArticleID="986086"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Low+CD4%2B+T-lymphocyte+T-cell+and+high+viral+load+precede+the+development+of+tuberculosis+disease+in+a+cohort+of+HIV-positive+Ethiopians.&amp;auth=&amp;atitle=Low+CD4%2B+T-lymphocyte+T-cell+and+high+viral+load+precede+the+development+of+tuberculosis+disease+in+a+cohort+of+HIV-positive+Ethiopians." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Low+CD4%2B+T-lymphocyte+T-cell+and+high+viral+load+precede+the+development+of+tuberculosis+disease+in+a+cohort+of+HIV-positive+Ethiopians." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Low+CD4%2B+T-lymphocyte+T-cell+and+high+viral+load+precede+the+development+of+tuberculosis+disease+in+a+cohort+of+HIV-positive+Ethiopians.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">38.
              </span><a name="pone.0000826-Eron1" id="pone.0000826-Eron1"></a>Eron JJ, Benoit SL, Jemsek J, et al.  (1995) Treatment with lamivudine, zidovudine or both in HIV- positive patients with 200–500 CD4+ T-lymphocyte cells per cubic millimeter. N Engl J Med  333: 1662–1669.  <ul class="find" data-citedArticleID="986028" data-doi="10.1056/nejm199512213332502"><li><a href="http://dx.doi.org/10.1056/nejm199512213332502" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Treatment+with+lamivudine%2C+zidovudine+or+both+in+HIV-+positive+patients+with+200%26%23x2013%3B500+CD4%2B+T-lymphocyte+cells+per+cubic+millimeter." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Treatment+with+lamivudine%2C+zidovudine+or+both+in+HIV-+positive+patients+with+200%26%23x2013%3B500+CD4%2B+T-lymphocyte+cells+per+cubic+millimeter.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">39.
              </span><a name="pone.0000826-Lawn1" id="pone.0000826-Lawn1"></a>Lawn SD, Bekker LG, Wood R (2005) How effectively does HAART restore immune response to mycobacterium tuberculosis? Implications for tuberculosis control. AIDS  19: 1113–1124.  <ul class="find" data-citedArticleID="986050" data-doi="10.1097/01.aids.0000176211.08581.5a"><li><a href="http://dx.doi.org/10.1097/01.aids.0000176211.08581.5a" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=How+effectively+does+HAART+restore+immune+response+to+mycobacterium+tuberculosis%3F+Implications+for+tuberculosis+control." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22How+effectively+does+HAART+restore+immune+response+to+mycobacterium+tuberculosis%3F+Implications+for+tuberculosis+control.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">40.
              </span><a name="pone.0000826-Lienhardt1" id="pone.0000826-Lienhardt1"></a>Lienhardt C, Rodrigues LC (1997) Estimation of the impact of human immunodeficiency virus infection on tuberculosis: tuberculosis risk revisited. Int J Tuberc Dis  1: 196–204.  <ul class="find" data-citedArticleID="986054"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Estimation+of+the+impact+of+human+immunodeficiency+virus+infection+on+tuberculosis%3A+tuberculosis+risk+revisited.&amp;auth=&amp;atitle=Estimation+of+the+impact+of+human+immunodeficiency+virus+infection+on+tuberculosis%3A+tuberculosis+risk+revisited." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Estimation+of+the+impact+of+human+immunodeficiency+virus+infection+on+tuberculosis%3A+tuberculosis+risk+revisited." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Estimation+of+the+impact+of+human+immunodeficiency+virus+infection+on+tuberculosis%3A+tuberculosis+risk+revisited.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">41.
              </span><a name="pone.0000826-Jorda1" id="pone.0000826-Jorda1"></a>Jorda R, Gold L, Cummins C, Hyde C (2002) Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. Br Med J  325: 757–760.  <ul class="find" data-citedArticleID="986048" data-doi="10.1136/bmj.324.7340.757"><li><a href="http://dx.doi.org/10.1136/bmj.324.7340.757" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Systematic+review+and+meta-analysis+of+evidence+for+increasing+numbers+of+drugs+in+antiretroviral+combination+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Systematic+review+and+meta-analysis+of+evidence+for+increasing+numbers+of+drugs+in+antiretroviral+combination+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">42.
              </span><a name="pone.0000826-Maher1" id="pone.0000826-Maher1"></a>Maher D, Borgdorff M, Boerma T (2005) HIV-related tuberculosis: how well are we doing with current control efforts? Int J Tuberc Lung Dis  9: 17–24.  <ul class="find" data-citedArticleID="986058"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=HIV-related+tuberculosis%3A+how+well+are+we+doing+with+current+control+efforts%3F&amp;auth=&amp;atitle=HIV-related+tuberculosis%3A+how+well+are+we+doing+with+current+control+efforts%3F" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HIV-related+tuberculosis%3A+how+well+are+we+doing+with+current+control+efforts%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HIV-related+tuberculosis%3A+how+well+are+we+doing+with+current+control+efforts%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">43.
              </span><a name="pone.0000826-World6" id="pone.0000826-World6"></a>World Health Organization (1999) Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec  74: 385–400.  <ul class="find" data-citedArticleID="986098"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Preventive+therapy+against+tuberculosis+in+people+living+with+HIV.&amp;auth=&amp;atitle=Preventive+therapy+against+tuberculosis+in+people+living+with+HIV." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Preventive+therapy+against+tuberculosis+in+people+living+with+HIV." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Preventive+therapy+against+tuberculosis+in+people+living+with+HIV.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">44.
              </span><a name="pone.0000826-World7" id="pone.0000826-World7"></a>             World Health Organization             2004             Isoniazid preventive therapy.             Report of a “lessons learnt” workshop of the six PROTEST pilot projects in Malawi, South Africa, and Zambia             Geneva             World Health Organization (WHO/HTM/TB/2004.336)In:27             30           <ul class="find-nolinks"></ul></li><li><span class="label">45.
              </span><a name="pone.0000826-World8" id="pone.0000826-World8"></a>World Health Organization (2006) Tuberculosis infection control in the era of expanding HIV care and treatment: addendum to WHO guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. Geneva: World Health Organization.   <ul class="find-nolinks"></ul></li><li><span class="label">46.
              </span><a name="pone.0000826-Wiktor1" id="pone.0000826-Wiktor1"></a>Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, et al.  (1999) Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet  353: 1469–1475.  <ul class="find" data-citedArticleID="986082" data-doi="10.1016/s0140-6736(99)03465-0"><li><a href="http://dx.doi.org/10.1016/s0140-6736(99)03465-0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Efficacy+of+trimethoprim-sulphamethoxazole+prophylaxis+to+decrease+morbidity+and+mortality+in+HIV-1-infected+patients+with+tuberculosis+in+Abidjan%2C+Cote+d%27Ivoire%3A+a+randomised+controlled+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Efficacy+of+trimethoprim-sulphamethoxazole+prophylaxis+to+decrease+morbidity+and+mortality+in+HIV-1-infected+patients+with+tuberculosis+in+Abidjan%2C+Cote+d%27Ivoire%3A+a+randomised+controlled+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">47.
              </span><a name="pone.0000826-World9" id="pone.0000826-World9"></a>World Health Organization (2002) Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. Geneva: World Health Organization.   <ul class="find-nolinks"></ul></li><li><span class="label">48.
              </span><a name="pone.0000826-Chintu1" id="pone.0000826-Chintu1"></a>Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, et al.  (2004) Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children: a double-blind randomised placebo-controlled trial. Lancet  364: 1865–71.  <ul class="find" data-citedArticleID="986016" data-doi="10.1016/s0140-6736(04)17442-4"><li><a href="http://dx.doi.org/10.1016/s0140-6736(04)17442-4" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Co-trimoxazole+as+prophylaxis+against+opportunistic+infections+in+HIV-infected+Zambian+children%3A+a+double-blind+randomised+placebo-controlled+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Co-trimoxazole+as+prophylaxis+against+opportunistic+infections+in+HIV-infected+Zambian+children%3A+a+double-blind+randomised+placebo-controlled+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">49.
              </span><a name="pone.0000826-Mocroft1" id="pone.0000826-Mocroft1"></a>Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al.  (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet  352: 1725–1730.  <ul class="find" data-citedArticleID="986064" data-doi="10.1016/s0140-6736(98)03201-2"><li><a href="http://dx.doi.org/10.1016/s0140-6736(98)03201-2" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Changing+patterns+of+mortality+across+Europe+in+patients+infected+with+HIV-1." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Changing+patterns+of+mortality+across+Europe+in+patients+infected+with+HIV-1.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">50.
              </span><a name="pone.0000826-Carmody1" id="pone.0000826-Carmody1"></a>Carmody ER, Ellie R, Diaz T, Starling P, Santos AP, et al.  (2003) An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic. Trop Med Int Health  8: 378–385.  <ul class="find" data-citedArticleID="986014" data-doi="10.1046/j.1365-3156.2003.01046.x"><li><a href="http://dx.doi.org/10.1046/j.1365-3156.2003.01046.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=An+evaluation+of+antiretroviral+HIV%2FAIDS+treatment+in+a+Rio+de+Janeiro+public+clinic." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22An+evaluation+of+antiretroviral+HIV%2FAIDS+treatment+in+a+Rio+de+Janeiro+public+clinic.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.XML" value="116781"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.PDF" value="235024"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t001.PNG_L" value="64740"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t001.PNG_M" value="85915"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t001.PNG_S" value="12478"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t001.TIF" value="304772"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t001.PNG_I" value="29235"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t002.PNG_L" value="175897"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t002.PNG_M" value="138332"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t002.PNG_S" value="18498"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t002.TIF" value="855414"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t002.PNG_I" value="104082"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t003.PNG_L" value="194335"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t003.PNG_M" value="101661"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t003.PNG_S" value="12279"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t003.TIF" value="920978"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t003.PNG_I" value="31794"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g001.PNG_L" value="79468"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g001.PNG_M" value="61562"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g001.PNG_S" value="10990"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g001.TIF" value="153614"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g001.PNG_I" value="23272"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t004.PNG_L" value="394081"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t004.PNG_M" value="165581"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t004.PNG_S" value="19023"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t004.TIF" value="1849186"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t004.PNG_I" value="70620"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t005.PNG_L" value="93896"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t005.PNG_M" value="130452"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t005.PNG_S" value="16210"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t005.TIF" value="398042"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.t005.PNG_I" value="44743"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g002.PNG_L" value="342396"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g002.PNG_M" value="54710"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g002.PNG_S" value="4376"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g002.TIF" value="634490"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000826.g002.PNG_I" value="19439"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000826&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000826" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000826&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0000826&volume=&issue=&title=Impact of Antiretroviral Therapy on the Incidence of Tuberculosis: The Brazilian Experience, 1995–2001&author_name=Abraham%20Miranda%2C%20Meade%20Morgan%2C%20Leda%20Jamal%2C%20Kayla%20Laserson%2C%20Draurio%20Barreira%2C%20Guida%20Silva%2C%20Joseney%20Santos%2C%20Charles%20Wells%2C%20Patricia%20Paine%2C%20Denise%20Garrett&start_page=1&end_page=9" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0000826" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826&amp;t=Impact%20of%20Antiretroviral%20Therapy%20on%20the%20Incidence%20of%20Tuberculosis%3A%20The%20Brazilian%20Experience%2C%201995%E2%80%932001" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826&title=Impact%20of%20Antiretroviral%20Therapy%20on%20the%20Incidence%20of%20Tuberculosis%3A%20The%20Brazilian%20Experience%2C%201995%E2%80%932001&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826&amp;title=Impact%20of%20Antiretroviral%20Therapy%20on%20the%20Incidence%20of%20Tuberculosis%3A%20The%20Brazilian%20Experience%2C%201995%E2%80%932001" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0000826&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Impact of Antiretroviral Therapy on the Incidence of Tuberculosis: The Brazilian Experience, 1995–2001';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0000826';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Impact%20of%20Antiretroviral%20Therapy%20on%20the%20Incidence%20of%20Tuberculosis%3A%20The%20Brazilian%20Experience%2C%201995%E2%80%932001 http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000826" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0000826" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">























          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Antiretroviral+therapy%22" title="Search for articles in the subject area:'Antiretroviral therapy'"><div class="flagText">Antiretroviral therapy</div></a>
              <div data-categoryid="32515" data-articleid="24490"
                   data-categoryname="Antiretroviral therapy"
                   class="flagImage" title="Flag 'Antiretroviral therapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Brazil%22" title="Search for articles in the subject area:'Brazil'"><div class="flagText">Brazil</div></a>
              <div data-categoryid="40323" data-articleid="24490"
                   data-categoryname="Brazil"
                   class="flagImage" title="Flag 'Brazil' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV%22" title="Search for articles in the subject area:'HIV'"><div class="flagText">HIV</div></a>
              <div data-categoryid="42663" data-articleid="24490"
                   data-categoryname="HIV"
                   class="flagImage" title="Flag 'HIV' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV+diagnosis+and+management%22" title="Search for articles in the subject area:'HIV diagnosis and management'"><div class="flagText">HIV diagnosis and management</div></a>
              <div data-categoryid="18941" data-articleid="24490"
                   data-categoryname="HIV diagnosis and management"
                   class="flagImage" title="Flag 'HIV diagnosis and management' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Highly-active+antiretroviral+therapy%22" title="Search for articles in the subject area:'Highly-active antiretroviral therapy'"><div class="flagText">Highly-active antiretroviral therapy</div></a>
              <div data-categoryid="35795" data-articleid="24490"
                   data-categoryname="Highly-active antiretroviral therapy"
                   class="flagImage" title="Flag 'Highly-active antiretroviral therapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Mycobacterium+tuberculosis%22" title="Search for articles in the subject area:'Mycobacterium tuberculosis'"><div class="flagText">Mycobacterium tuberculosis</div></a>
              <div data-categoryid="42725" data-articleid="24490"
                   data-categoryname="Mycobacterium tuberculosis"
                   class="flagImage" title="Flag 'Mycobacterium tuberculosis' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22T+cells%22" title="Search for articles in the subject area:'T cells'"><div class="flagText">T cells</div></a>
              <div data-categoryid="40147" data-articleid="24490"
                   data-categoryname="T cells"
                   class="flagImage" title="Flag 'T cells' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Tuberculosis%22" title="Search for articles in the subject area:'Tuberculosis'"><div class="flagText">Tuberculosis</div></a>
              <div data-categoryid="47969" data-articleid="24490"
                   data-categoryname="Tuberculosis"
                   class="flagImage" title="Flag 'Tuberculosis' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=8132'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=1557'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=4393&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>

<div class="block sidebar-comments">
    <div class="header">
        <h3>Comments</h3>
    </div>
      <p><a href="/annotation/listThread.action?root=13479">PLoS ONE Group</a><br>Posted by PLoS_ONE_Group</p>
</div>

</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
